Rhythm's HO Launch Gains Early Traction, Revenue Surges to $60.1M

What happened

Rhythm Pharmaceuticals reported Q1 2026 net product revenue of $60.1 million, more than 80% above the prior year quarter, driven by the initial U.S. launch of IMCIVREE in acquired hypothalamic obesity (HO) with over 150 patient start forms received in the first six weeks. The European Commission also granted marketing authorization for HO, and the Japanese NDA remains under review. While the early HO adoption is stronger than expected and supports the bull case, the company continues to generate substantial operating losses, with Q1 expenses likely tracking above the guided $295-315M non-GAAP opex range. Cash and investments of $416M provide roughly two years of runway, but the revenue-interest financing on IMCIVREE assets adds leverage. The launch is encouraging, but sustained payer coverage, patient persistence, and expense discipline must improve before the stock justifies its premium valuation.

Implication

If HO adoption sustains for two quarters, Rhythm could grow into its valuation, but monitor payer access, SG&A growth, and cash burn. A pullback to ~$80 on any execution noise would offer a better entry.

Thesis delta

Initial HO launch metrics are stronger than modeled in the bear case, reducing near-term downside risk and increasing the probability of a successful launch. However, the company remains deeply unprofitable and reliant on external capital; the bull case probability rises to ~30% from 25% if launch momentum continues for two quarters. The WAIT rating is maintained as margin of safety remains thin, and we need to see sustained revenue growth without disproportionate cost inflation.